青山紙業(600103.SH):子公司擬投建兩條全自動多用途複合材料包裝制袋生產線
格隆匯3月28日丨青山紙業(600103.SH)公佈,鑑於前期福建省青山紙業股份有限公司成立的全資子公司廣州青紙包裝材料有限公司發展模式已實現規模效益化,為進一步加快推進公司漿紙產業鏈延伸,開拓福建本省紙袋生產銷售業務市場,藉助公司的原料供應與客户渠道資源優勢,鞏固“青山”牌紙袋紙在本省乃至周邊省份區域的銷售業務穩步提高,並藉助“新版限塑令”下工業紙袋的政策紅利及新《水泥包裝袋》生產標準實施為企業建設制袋生產線項目帶來的機遇,公司全資子公司沙縣青晨貿易有限公司(簡稱“沙縣青晨”)擬投資建設兩條全自動多用途複合材料包裝制袋生產線,項目總投資4939.46萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.